ASH 2023 | Investigating a novel trispecific TCE for patients with myeloma who relapse on anti-CD38 antibodies
Aintzane Zabaleta, University of Navarra, Pamplona, Spain, evaluates the use of a CD38/CD28xCD3 tri-specific T-cell engager (TCE), SAR442257, for the treatment of patients with relapsed/refractory (R/R) multiple myeloma (MM). Most patients relapse following anti-CD38 monoclonal antibody (mAb) therapies, with poor natural killer (NK) cell responses, and alternative treatment options are therefore needed. This TCE showed clinical activity, inducing lysis of tumor cells. However, to observe this efficacy, a washout period was required to recover CD38 expression and remove previous mAb treatments from the system of the patient. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
